Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Trial Profile

Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 03 Dec 2018 Planned initiation date changed from 1 Feb 2019 to 1 May 2019.
    • 19 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top